NovaBay Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. announced an agreement for the sale and marketing of Avenova®?-branded products by Sonoma in the European Union. The new products will combine Sonoma's existing eye product Ocudox®?, which has already received a Class IIB CE mark for sale in the European Union, with Avenova brand, and are expected to be marketed through Sonoma's established European distribution network. This agreement brings together NovaBay's deep knowledge of eye care reflected in its Avenova brand with Sonoma's expertise in distributing hypochlorous acid products overseas.

Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay's Avenova products, which are the leading hypochlorous acid-based eye care products in the U.S. Sonoma will pay NovaBay a royalty fee based on net product sales of Ocudox by Avenov, and Sonoma will continue to market its Ocudox product in the European Union.